Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for BioLight Life Sciences's Days Payable or its related term are showing as below:
During the past 13 years, BioLight Life Sciences's highest Days Payable was 1558.95. The lowest was 136.43. And the median was 844.69.
XTAE:BOLT's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 112.84 * Ranked among companies with meaningful Days Payable only.
BioLight Life Sciences's Days Payable
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:BOLT vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, BioLight Life Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLight Life Sciences Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioLight Life Sciences's Days Payable distribution charts can be found below:
* The bar in red indicates where BioLight Life Sciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
BioLight Life Sciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioLight Life Sciences (XTAE:BOLT) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioLight Life Sciences and its competitors. Over the past decade, BioLight Life Sciences' Days Payable has ranged from 136.43 to 1,558.95. According to the industry distribution chart, BioLight Life Sciences ranks #999999 out of 703 companies in the Biotechnology industry.
Is BioLight Life Sciences' Days Payable too high?
BioLight Life Sciences' current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 136.43 to a high of 1,558.95. Based on the distribution chart, BioLight Life Sciences ranks #999999 out of 703 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioLight Life Sciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does BioLight Life Sciences' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioLight Life Sciences ranks #999999 out of 703 companies for Days Payable. This places BioLight Life Sciences in the lower half of its industry. The industry median Days Payable is 112.84. Historically, BioLight Life Sciences' own Days Payable has ranged from 136.43 to 1,558.95 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioLight Life Sciences and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLight Life Sciences's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLight Life Sciences stock overvalued right now?
BioLight Life Sciences (XTAE:BOLT) has a current Days Payable of 0.00. The current Days Payable is 0.00. BioLight Life Sciences' overall GF Score™ is 16/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For BioLight Life Sciences (XTAE:BOLT), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioLight Life Sciences Ltd is an emerging ophthalmic company. It is engaged in the discovery, development, and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome and age-related macular degeneration. The firm's products include ioptimate, eye-d technology, and diagnostear. The company has the Eye cluster and the Cancer diagnostics cluster operating segments. It derives the majority of its revenues from the Eye cluster segment.
16GF Score
Get the complete analysis for XTAE:BOLT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:BOLT has been successfully added to your 
